Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 14
Submit an article Journal homepage
277
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Successful combination treatment with azacitidine and venetoclax for a patient with acute myeloid leukemia undergoing hemodialysis

Taro Edahiroa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
,
Hiroshi Ureshinoa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, JapanCorrespondence[email protected], [email protected]
ORCID Iconhttps://orcid.org/0000-0002-5034-3699
ORCID Icon,
Ren Chishakia Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
,
Keita Fujinoa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
,
Tatsuji Minoa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
,
Tetsumi Yoshidaa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
,
Noriyasu Fukushimaa Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan;b Department of Internal Medicine, Karatsu Red Cross Hospital, Karatsu, Japan
&
Tatsuo Ichinohea Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
 show all
Pages 3511-3512 | Received 29 Jun 2022, Accepted 02 Sep 2022, Published online: 13 Sep 2022

References

  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Ofran Y, Tallman MS, Rowe JM. How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood. 2016;128(4):488–496.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–1032.
  • Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
  • Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404–e407.
  • DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407.
  • Janus N, Launay-vacher V, Thyss A, et al. Management of anticancer treatment in patients under chronic dialysis: Results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol. 2013;24(2):501–507.
  • Kaminskas E, Farrell AT, Wang Y-C, et al. FDA drug approval summary: Azacitidine (5-azacytidine, VidazaTM) for injectable suspension. Oncologist. 2005;10(3):176–182.
  • Ham JC, Hoogendijk-Van Den Akker JM, Verdonck LF. A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine. Leuk Lymphoma. 2012;53(12):2521–2522.
  • Yoshihiro T, Muta T, Aoki K, et al. Efficacy and adverse events of azacitidine in the treatment of hemodialysis patients with high-risk myelodysplastic syndrome. Rinsho Ketsueki. 2016;57(8):1004–1010.
  • Douvali E, Papoutselis M, Vassilakopoulos TP, et al. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment. Leuk Res. 2013;37(8):889–893.
  • Batty GN, Kantarjian H, Issa J, et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk. 2010;10(3):205–210.
  • Salem AH, Agarwal SK, Dunbar M, et al. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or Non-Hodgkin lymphoma. J Clin Pharmacol. 2017;57(4):484–492.
  • Swan D, Delaney C, Natoni A, et al. Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14). Haematologica. 2020;105(3):e141–e143.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.